Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaAnthony R. Mato, Wojciech Jurczak, Krish Patel et al.|New England Journal of Medicine|2023Cited by 213
Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN StudyAnthony R. Mato, Wojciech Jurczak, John M. Pagel et al.|Blood|2021Cited by 15